Value in health regional issues最新文献

{"title":"Societal Preferences for Subsidizing Treatments Targeting Patients With Advanced Illness: A Discrete Choice Experiment","authors":"Drishti Baid BSocSci ,&nbsp;Darius N. Lakdawalla PhD ,&nbsp;Eric A. Finkelstein PhD","doi":"10.1016/j.vhri.2024.101003","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101003","url":null,"abstract":"<div><h3>Objectives</h3><p>Cost-effectiveness analyses are increasingly used to inform subvention decisions for moderately life extending treatments but apply several simplifying assumptions that may be inconsistent with public preferences. Contrary to standard assumptions, we hypothesize that societal willingness to allocate public funding toward these treatments is (1) diminishing for incremental improvements in survival and quality of life (QoL) and (2) greater for subvention policies that exclude the oldest old (&gt;80 years).</p></div><div><h3>Methods</h3><p>We tested these hypotheses using a web-based discrete choice experiment (<em>n</em> = 425) in Singapore. In each of 5 questions, respondents were shown 2 hypothetical treatments targeting patients with an expected prognosis of 2 months at very poor QoL and asked which treatment they wanted the government to subsidize, if any. Treatments were defined by 4 attributes: cost to the government, age of beneficiaries, expected gain in survival (2-12 months), and QoL (poor, fair, and good).</p></div><div><h3>Results</h3><p>Latent class models were used to analyze results. Results revealed 2 classes. In the majority class (69.7% of sample), respondents value incremental gains in survival and QoL at a diminishing rate. Their willingness to allocate public funding estimates (Singapore dollars 16 825-91 027 per patient per month) were much higher than traditional cost-effectiveness thresholds. In the second class, respondents were unwilling to subsidize treatments offering less than 2 months of life extension or poor QoL. Neither class preferred subvention policies that exclude the oldest old.</p></div><div><h3>Conclusions</h3><p>These findings suggest that the Singapore government should consider cost-effectiveness thresholds that rise with increases in life extension. Age-based restrictions should not be imposed.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101003"},"PeriodicalIF":2.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141244999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran","authors":"Mohsen Choband Molaee PharmD ,&nbsp;Zahra Gharib Naseri PharmD, PhD ,&nbsp;Masoud Ali Karami PharmD, PhD","doi":"10.1016/j.vhri.2024.101002","DOIUrl":"10.1016/j.vhri.2024.101002","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to determine long-term cost-effectiveness of continuous glucose monitoring (CGM) technology versus self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D) using multiple daily injections in Iran.</p></div><div><h3>Methods</h3><p>According to available data, the long-term costs and clinical outcomes of CGM and SMBG were estimated using the Sheffield Type 1 Diabetes Model, with a lifetime horizon from a payer’s perspective. The primary outcome was the cost per quality-adjusted life year (QALY) gained.</p></div><div><h3>Results</h3><p>The lifetime cost-effectiveness analysis demonstrated that on average, the use of CGM increased life expectancy by 1.32 years and QALYs by 1.63, compared with SMBG. The CGM group had an average discounted total cost of $40 093 US dollars, whereas the SMBG group had an average discounted total cost of $13 366. This resulted in an incremental cost-effectiveness ratio (ICER) of $16 386 per QALY gained, which is less than the threshold of 3 times the gross domestic product (GDP) per capita of Iran ($24 561).</p></div><div><h3>Conclusions</h3><p>Considering 3 times the GDP per capita as the threshold, CGM is likely to be cost-effective in Iran. However, for CGM to be very cost-effective (ie, have an ICER less than 1 times the GDP per capita) and presumably more accessible, the price of CGM should decrease to $40 per sensor, each with a lifespan of 14 days.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101002"},"PeriodicalIF":2.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and Reflections on Pandemic Disinformation: The Case of Hydroxychloroquine and the Implications for Global Public Health","authors":"Heslley Machado Silva PhD","doi":"10.1016/j.vhri.2024.101005","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101005","url":null,"abstract":"<div><p>This text addresses the implications of misinformation during the COVID-19 pandemic, focusing on the use of hydroxychloroquine (HCQ) and other drugs based on a specific publication. The article titled “Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate,” published in 2024 in the journal Biomedicine and Pharmacotherapy, reveals 17 000 deaths associated with the inappropriate use of HCQ in 6 countries, excluding Brazil and India. The dissemination of ineffective drugs, the persistence in recommending HCQ in Brazil, and the lack of an effective response from academia underscore the fragility of public health systems under pressure. Transparent communication between the scientific community and the public is vital, particularly considering studies, such as the one published in Nature Communications in 2021, which warns of the risks of chloroquine. The text highlights the influence of social media in spreading unverified information and emphasizes the need for criminal liability for those contributing to the spread of misinformation. It concludes by underlining the importance of learning from past mistakes to build a more resilient and informed future in the field of public health.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101005"},"PeriodicalIF":2.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Process of Listing Prostheses and Medical Devices in Thailand’s Universal Health Coverage","authors":"Manthana Laichapis PharmD ,&nbsp;Thanisa Thathong PharmD ,&nbsp;Supisara Kanjanaphrut PharmD ,&nbsp;Sirada Thansuwanwong PharmD ,&nbsp;Yotsaya Kunlamas PharmD ,&nbsp;Puree Anantachoti PhD ,&nbsp;Bunchai Chongmelaxme PhD","doi":"10.1016/j.vhri.2024.100990","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100990","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to characterize the processes of listing prostheses and medical devices in all insurance schemes.</p></div><div><h3>Methods</h3><p>A literature review was performed, and in-depth interviews were conducted with the representatives of 6 insurance agencies. Civil Servant Medical Benefits Scheme (CSMBS), Social Security Scheme, Local Government Officer Scheme (LGOS), State Enterprise Scheme (SES), Universal Coverage Scheme (UCS), and Non-Thai Resident Scheme (NTRS).</p></div><div><h3>Results</h3><p>The outcomes of interest were structure details and the body of the working groups, listing processes, and key assessment criteria. Each insurance scheme’s process can be summarized in 5 steps: (1) receiving the proposed topics of health technologies, (2) screening, (3) selection, (4) consideration, and (5) approval and publicization. Notably, the organizational structures and working group compositions vary across schemes, leading to differences in process activities and assessment criteria. LGOS and SES are exceptions because they follow the application process of CSMBS. UCS demonstrates the most transparent process, providing specific working groups that are competent in undertaking each activity. The processes of listing prostheses and medical devices vary across health insurance in Thailand, leading to varying numbers of health technologies covered by insurance schemes.</p></div><div><h3>Conclusions</h3><p>This study characterizes prostheses and medical device listing processes in 6 Thai Universal Health Coverage insurance schemes (CSMBS, Social Security Scheme, UCS, LGOS, SES, and Non-Thai Resident Scheme). Variations in processes result in differing technology listings. It offers essential insights for healthcare professionals and policy makers.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100990"},"PeriodicalIF":2.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of COVID-19 on Healthcare Utilization in Turkey","authors":"Zeynep B. Uğur PhD ,&nbsp;Ayşenur Durak MSc","doi":"10.1016/j.vhri.2024.101000","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101000","url":null,"abstract":"<div><h3>Objectives</h3><p>This study investigates the impact of the COVID-19 pandemic on healthcare utilization in Turkey.</p></div><div><h3>Methods</h3><p>We utilized individual-level data derived from Turkish Statistical Institute’s annual surveys between 2014 and 2022 and estimated probit regression models.</p></div><div><h3>Results</h3><p>We find that COVID-19 pandemic reduced healthcare utilization by 11.8% after taking into account a large set of background variables. Although our study finds that the elderly and those with health problems are more likely to use healthcare services under normal circumstances, the COVID-19 pandemic has caused notable drops in the healthcare utilization among the elderly (−6.5%) and those with health problems (−3.8%). Although those without health insurance had lower utilization of healthcare services before the pandemic, during the pandemic they were not particularly hit.</p></div><div><h3>Conclusion</h3><p>We conclude that the pandemic did not lower the healthcare utilization in Turkey because of the supply constraints. Also, the evidence points to the reduced demand due to the fear of contagion rather than financial concerns.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101000"},"PeriodicalIF":2.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortalidad, Secuelas Clínicas y Calidad de Vida Luego del Alta de Unidades de Cuidados Intensivos en Pacientes con COVID-19: Estudio Multicéntrico Descriptivo en Argentina","authors":"Fernando Argento Ms(c) ,&nbsp;Manuel Donato Ms(c) ,&nbsp;Dario Villalba Spec ,&nbsp;Marisol García Sarubbio Spec ,&nbsp;Anabella Giménez PT ,&nbsp;Agustin Ciapponi PhD ,&nbsp;Federico Augustovski PhD","doi":"10.1016/j.vhri.2024.100989","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100989","url":null,"abstract":"<div><h3>Objective</h3><p>Patients with COVID-19 who require hospitalization in an intensive care unit, in addition to being at risk of presenting premature death, have higher rates of complications. This study aimed to describe mortality, rehospitalizations, quality of life, and symptoms related to postintensive care syndrome (PICS) and prolonged COVID-19 in patients with COVID-19 discharged from the intensive care unit in hospitals in Argentina.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in 4 centers in the Autonomous City and province of Buenos Aires as of December 2022. The variables of interest were mortality after discharge, rehospitalization, health-related quality of life, post-COVID-19–related symptoms, cognitive status, and PICS. Data collection was by telephone interview between 6 and 18 months after discharge.</p></div><div><h3>Results</h3><p>A total of 124 patients/families were contacted. Mortality was 7.3% (95% CI: 3.87-13.22) at 14.46 months of follow-up after discharge. Patients reported a reduction of the EQ-5D-3L visual analog scale of 13.8 points, reaching a mean of 78.05 (95% CI: 73.7-82.4) at the time of the interview. Notably, 54.4% of patients (95% CI: 41.5-66.6) reported cognitive impairment and 66.7% (95% CI: 53.7-77.5) developed PICS, whereas 37.5% (95% CI: 26-50.9) had no symptoms of prolonged COVID-19.</p></div><div><h3>Conclusion</h3><p>The results showed a significant impact on the outcomes studied, consistent with international evidence.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100989"},"PeriodicalIF":2.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?","authors":"Gaurav Jyani PhD ,&nbsp;Nidhi Gupta MD","doi":"10.1016/j.vhri.2024.100991","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100991","url":null,"abstract":"<div><p>In recent years, newer drugs, such as ibrutinib, have shown promising improvements in the survival of patients with chronic lymphocytic leukemia (CLL). Despite their effectiveness, concerns about their cost have arisen, prompting the need for an evaluation of their cost-effectiveness. However, recent assessments of ibrutinib’s cost-effectiveness for treating CLL in India reveal divergent conclusions. The discord centers on divergent cost-effectiveness thresholds, comparator regimens, cost calculations, and outcome valuation approaches. Such discrepancies affect public health decisions and patient care. The recommendation calls for adherence to methodological guidelines by future studies, fostering consistent findings to empower policy makers and clinicians in leveraging economic evidence for informed decision making in CLL treatment strategies.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100991"},"PeriodicalIF":2.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140879217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Transfusion-Dependent Thalassemia Patients in Greece Before and During the COVID-19 Pandemic","authors":"Philippos Klonizakis PhD ,&nbsp;Robert J. Klaassen PhD ,&nbsp;Noémi Roy PhD ,&nbsp;Ioanna Papatsouma PhD ,&nbsp;Maria Mainou MSc ,&nbsp;Ioanna Christodoulou BHSc ,&nbsp;Apostolos Tsapas PhD ,&nbsp;Efthymia Vlachaki PhD","doi":"10.1016/j.vhri.2024.100986","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100986","url":null,"abstract":"<div><h3>Objectives</h3><p>The peak of the COVID-19 pandemic was a challenging situation for transfusion-dependent thalassemia (TDT) patients. The objectives of this study were to measure the quality of life (QoL) in TDT patients during the COVID-19 lockdown restriction measures, compare the results with the pre-COVID-19 era, and evaluate the influence of sociodemographic and clinical factors on QoL.</p></div><div><h3>Methods</h3><p>This was a cross-sectional study of 110 consecutively selected adult TDT patients, during the stringent lockdown restriction measures implemented in Greece. All participants completed a combination of 2 QoL questionnaires, the generic Short-Form Health Survey 36 version 2 and the disease-specific Transfusion-Quality of life (TranQol). We used the “1/2 SD method,” a distribution-based approach to calculate minimal clinically important differences and clinically compare the QoL scores between the pre-COVID-19 and post-COVID-19 era. A backward stepwise linear regression was selected to explore the influence of potential predictors on TranQol scores.</p></div><div><h3>Results</h3><p>The Short-Form Health Survey 36 version 2 and TranQol scores remained low but not clinically different compared with the pre-COVID-19 era. Older, married, and higher educated TDT patients exhibited significantly lower TranQol summary scores. The patients who reported a negative effect of the COVID-19 pandemic had significantly lower TranQol scores in summary and all subdomains except for school and career.</p></div><div><h3>Conclusions</h3><p>During the COVID-19 pandemic, the overall QoL of TDT patients was clinically similar to the status of the pre-COVID-19 era. Nevertheless, most of the significant QoL subdomains were negatively affected, and distinct groups of TDT patients were more vulnerable.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100986"},"PeriodicalIF":2.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews","authors":"Marília Berlofa Visacri PhD ,&nbsp;Mayra Carvalho Ribeiro MSc ,&nbsp;Denis Satoshi Komoda ,&nbsp;Bruno Kosa Lino Duarte PhD ,&nbsp;Carlos Roberto Silveira Correa PhD ,&nbsp;Flávia de Oliveira Motta Maia PhD ,&nbsp;Daniela Fernanda dos Santos Alves PhD","doi":"10.1016/j.vhri.2024.100998","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100998","url":null,"abstract":"<div><h3>Objectives</h3><p>To present an overview of evidence of efficacy, safety, and health-related quality of life of lenalidomide or thalidomide for transplant-ineligible multiple myeloma.</p></div><div><h3>Methods</h3><p>A literature search was performed in 5 databases until July 2022. We included systematic reviews with network meta-analyses of randomized controlled trials on the use of lenalidomide compared with thalidomide for transplant-ineligible multiple myeloma. The A Measurement Tool to Assess Systematic Reviews 2 was used to appraise the quality of included reviews. The results were focused on the lenalidomide + dexamethasone until disease progression (RDc) versus thalidomide + dexamethasone until disease progression (TDc) and induction with melphalan + prednisone + lenalidomide, followed by maintenance with lenalidomide (MPR-R) versus induction with melphalan + prednisone + thalidomide, followed by maintenance with thalidomide (MPT-T) regimens.</p></div><div><h3>Results</h3><p>Nine studies were included. Only 1 study did not show any weakness in critical domains of A Measurement Tool to Assess Systematic Reviews 2. For overall survival, RDc proved to be superior to TDc; however, no study showed significant difference between MPR-R and MPT-T. For progression-free survival, 2 of 3 studies showed that RDc is better than TDc; however, no difference between MPR-R and MPT-T was found. Regarding safety, these lenalidomide-based regimens had a lower risk for neurologic adverse events, with an increased risk of hematologic adverse events. No health-related quality of life meta-analyses were found.</p></div><div><h3>Conclusions</h3><p>These findings suggest that, in terms of efficacy and safety, lenalidomide-based regimen is a good option for treatment of transplant-ineligible multiple myeloma in the public health system of Brazil, especially for those patients who develop severe neuropathy with thalidomide.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 100998"},"PeriodicalIF":2.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140880280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microcosting Analysis of Advanced Ovarian Cancer: Real-World Evidence From the Perspective of a Reference Public Brazilian Hospital","authors":"Carolina Martins BPharm ,&nbsp;Raquelaine Padilha BSN, MSc ,&nbsp;Lucas Okumura BPharm, MSc ,&nbsp;Andreia Melo MD, MSc, PhD ,&nbsp;Rodrigo Costa BPharm, PhD","doi":"10.1016/j.vhri.2024.100999","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100999","url":null,"abstract":"<div><h3>Objectives</h3><p>Evaluate the cost of advanced ovarian cancer, using the microcosting technique, based on real-world evidence from the perspective of a reference Brazilian public hospital.</p></div><div><h3>Methods</h3><p>Retrospective cohort study of patients newly diagnosed with advanced ovarian cancer in 2017 and followed-up for up to 5 years. A bottom-up microcosting method was applied, using the activity-based cost approach, which evaluates service costs based on activity consumption throughout patients’ journey.</p></div><div><h3>Results</h3><p>The results indicate a median overall survival of 35.3 months and a median age of 57 years (33-80 years old). The average cost per patient was USD 34 991.595 over a period of 35.3 months, with admissions because of the disease progression and end-of-life care being the most relevant.</p></div><div><h3>Conclusions</h3><p>The results show that the costs of activities currently involved in the treatment of advanced ovarian cancer represent an important economic impact for the public health system. These data can support future analyses on the impact of incorporating new technologies for the treatment of ovarian cancer and on the financing and sustainability of the Brazilian public healthcare system.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 100999"},"PeriodicalIF":2.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}